New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
09:09 EDTPRANPrana completes recruitment in IMAGINE trial
Prana Biotechnology announced that it has completed recruitment in the IMAGINE trial, a 12 month Phase II trial testing PBT2, the Company's drug in development for Alzheimer's Disease. The double-blind placebo controlled trial has enrolled 41 patients with prodromal or mild Alzheimer's Disease in Melbourne, Australia. One additional patient may be included in the trial, subject to final screening procedures this week. All trial participants are undergoing brain scans to measure PBT2's effect on amyloid deposits in the brain and effects on increasing brain activity.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
16:27 EDTPRANPrana updates Alzheimer disease development program
Prana Biotechnology has provided an update on its clinical development program for Alzheimer's disease. In Professor Colin Masters' July presentation, which includes data from Prana's phase 2 IMAGINE and EURO trials, he noted that the starting amyloid burden level in the PBT2 treated participant group had an important bearing on the decrease of amyloid over time in that participant, whereas there was no such correlation in the placebo group. Separately, Prana has confirmed the top line finding that there is a very promising trend towards the preservation of brain volume in PBT2 treated patients compared to placebo patients.
11:00 EDTPRANHigh option volume stocks
High option volume stocks: OMC FXC TSEM JRJC MAT MTG PRAN SEAS BURL

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use